Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813108 | 0.85 | CLK4 (0.44) | CLK4DYRK1AADRB2CYP4F2CYP4A11 | |
| SCHEMBL31500156 | 0.83 | CYP4F2 (0.46) | CYP4F2CYP4A11TRPA1ALDH1A1TSHR | |
| SCHEMBL8684507 | 0.83 | CYP4F2 (0.40) | CLK4DYRK1ACYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL1259618 | 0.80 | TRPA1 (0.52) | CYP4F2CYP4A11TRPA1ALDH1A1TSHR | |
| SCHEMBL30987236 | 0.80 | TRPA1 (0.52) | CYP4F2CYP4A11TRPA1ALDH1A1TSHR | |
| SCHEMBL2130914 | 0.80 | PRKCI (0.61) | CLK4DYRK1AADRB2HCRTR1HCRTR2 | |
| SCHEMBL112429 | 0.80 | ADRB2 (0.68) | CLK4DYRK1AADRB2CYP2A6 | |
| SCHEMBL29676764 | 0.80 | ADRB2 (0.68) | CLK4DYRK1AADRB2CYP2A6 | |
| SCHEMBL20738473 | 0.80 | CLK4 (0.47) | CLK4DYRK1AADRB2CYP2A6HCRTR1 | |
| SCHEMBL6848165 | 0.80 | CLK4 (0.47) | CLK4DYRK1AADRB2CYP2A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-08-09 | — | — | US | disclosed |
| US-9938269-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2018-04-10 | — | — | US | disclosed |
| CN-103958504-B | 10A type phosphodiesterase inhibitor compound | 艾伯维德国有限责任两合公司 | 2016-10-12 | — | — | CN | disclosed |
| EP-2726479-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2014-05-07 | — | — | EP | disclosed |
| EP-2516439-B1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| EP-2516439-B1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| EP-2516439-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| WO-2012055888-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | NOVARTIS PHARMA AG (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | REN, PKD1, NR3C2 | CLK4 3645/4885DYRK1A 1618/4885ADRB2 52/4885 |
| US-20130281463-A1 | DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | CLK4 4647/4885DYRK1A 1707/4885ADRB2 62/4885 |
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | CLK4 4266/4885DYRK1A 2392/4885ADRB2 738/4885 |
| US-20120101110-A1 | Diaza-spiro[5.5]undecanes | REN, PKD1, NR3C2 | CLK4 3656/4885DYRK1A 1415/4885ADRB2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.